Form 8.3 - Dechra Pharmaceuticals Plc
15 Enero 2024 - 9:30AM
UK Regulatory
TIDMDPH
U.K. DISCLOSURE, Jan. 15, 2024 (GLOBE NEWSWIRE) --
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Identity of the person whose positions/dealings Glazer Capital
are being disclosed: LLC
---------------------------------------------------------------- ---------------
(b) Owner or controller of interests and short positions NA
disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
---------------------------------------------------------------- ---------------
(c) Name of offeror/offeree in relation to whose relevant Dechra
securities this form relates: Pharmaceuticals
Use a separate form for each offeror/offeree plc
---------------------------------------------------------------- ---------------
(d) If an exempt fund manager connected with an offeror/offeree, NA
state this and specify identity of offeror/offeree:
---------------------------------------------------------------- ---------------
(e) Date position held/dealing undertaken: January 12,
2024
---------------------------------------------------------------- ---------------
(f) Has the discloser previously disclosed, or are NO
they today disclosing, under the Code in respect of
any other party to this offer?
---------------------------------------------------------------- ---------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: 1p ordinary
-------------------------------------- --------------------------------------
Interests Short positions
-------------------------------------- ------------------- -----------------
Number % Number %
-------------------------------------- --------- -------- ------------ ---
(1) Relevant securities owned and/or
controlled:
-------------------------------------- --------- -------- ------------ ---
(2) Derivatives (other than options): 3,160,711 2.77%
-------------------------------------- --------- ---- ------------ ---
(3) Options and agreements to
purchase/sell:
-------------------------------------- --------- -------- ------------ ---
TOTAL: 3,160,711 2.77%
-------------------------------------- --------- ---- ------------ ---
All interests and all short positions should be disclosed.
Details of any open derivative or option positions, or
agreements to purchase or sell relevant securities, should be given
on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other executive options)
Class of relevant security in relation to which subscription
right exists:
------------------------------------------------------------
Details, including nature of the rights concerned
and relevant percentages:
------------------------------------------------------------
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
(a) Purchases and sales
Class of relevant Purchase/sale Number of securities Price per unit
security
------------------------- ------------- -------------------- --------------
(b) Derivatives transactions (other than options)
Class of Product description Nature of dealing Number of Price
relevant e.g. CFD e.g. opening/closing a long/short position, increasing/reducing reference per
security a long/short position securities unit
-------- ------------------- ---------------------------------------------------------------- ---------- -----
1p Total return swap Reducing a long position 100,000 38.66
ordinary GBP
-------- ------------------- ---------------------------------------------------------------- ---------- -----
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry Option
relevant description purchasing, securities price e.g. American, European etc. date money
security e.g. call selling, to which per paid/
option varying option unit received
etc. relates per
unit
-------- ----------- ----------- ---------- -------- ----------------------------- ------ --------
(ii) Exercising
Class of relevant Product description Number of Exercise price per
security e.g. call option securities unit
----------------- ------------------- ------------------ ------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit
security e.g. subscription, conversion (if applicable)
------------------ ------------------------------ ------- -----------------
The currency of all prices and other monetary amounts should be
stated.
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or
any agreement or understanding, formal or informal,
relating to relevant securities which may be an inducement
to deal or refrain from dealing entered into by the
person making the disclosure and any party to the
offer or any person acting in concert with a party
to the offer:
If there are no such agreements, arrangements or understandings,
state "none"
-----------------------------------------------------------------
None
-----------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding,
formal or informal, between the person making the
disclosure and any other person relating to:
(i) the voting rights of any relevant securities under
any option; or
(ii) the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
is referenced:
If there are no such agreements, arrangements or understandings,
state "none"
-----------------------------------------------------------------
None
-----------------------------------------------------------------
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
---------------------------------------------------
Date of disclosure: January 15, 2024
-------------------- ----------------
Contact name: Ava Lederer
-------------------- ----------------
Telephone number: 212-808-7306
-------------------- ----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at
https://www.globenewswire.com/Tracker?data=7cciweYbtkY28aLNzoeudWWI27wJbK8TBBQW5FPal7QPvLVtBOlYHfkFuxwj1o7SkKAajBPrRT2lg2ImDCZL3ER2nUrmmZoGMGaWAcHz8ZOI2LKDxA1Toggpt3egAuq4
monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit
is available for consultation in relation to the Code's dealing
disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
https://www.globenewswire.com/Tracker?data=Dqn_mOj-2Izat9YGjfmVbtCG6voXJlypQVKwKmf-1GT6R9GcCDfWu-Eeuhw5-MCordAIM9gALx_jPkff9uv81olLWX5Vlr_aq-3KskDgl0kkXmdI7Xfky1E3i3R2yjzS
www.thetakeoverpanel.org.uk.
(END) Dow Jones Newswires
January 15, 2024 10:30 ET (15:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
